66 results about "Cannabivarin" patented technology

The present invention relates to the use of cannabidiol (CBD) in the treatment of Sturge Weber syndrome. CBD ap-pears particularly effective in reducing all types of seizures and non-seizure symptoms in patients suffering with Sturge Weber syndrome. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w / w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocan-nabinol (THC) has been substantially removed, to a level of not more than 0.15% (w / w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.

A fatty acid ester of cannabinoid, wherein the fatty acid is an unsaturated acid, with an ester linkage consisting of an aryloxy oxygen directly bonded to an aromatic ring of the cannabinoid and a carbonyl group attached to the fatty acid unsaturated carbon chain.

Apparatus and methods are provided for dispensing into a liquid a soluble substance, such as a soluble flavoring. The soluble flavoring may include a lime flavoring with citric acid. It may include a cannabinoid. Alternatively, the soluble flavoring may not include citric acid or sugar. A useful application of the subject invention includes a lime flavoring held by a gelatinous elastic lime wedge. The gelatinous lime wedge may be retrieved from a protective covering and acted upon so it mixes the lime flavoring into a beverage, such as when it's inserted into a water or beer bottle or can. Rather than needing to buy and store a perishable natural lime, and cut it up, a gelatinous lime wedge holding soluble lime flavoring may be stored for an extended period of time, and placed in functional contact with water, beer, or other liquid, at time of consumption.

Cannabinoid compositions formulated for use in the treatment of post-traumatic epilepsy (PTE) are disclosed. The compositions include cannabidiol (CBD), cannabigerol (CBG), and tetrahydrocannabinol (THC) as the major components therein, which may be isolated, purified or extracted from cultivars and blended together. The compositions include CBD, CBG and THC in certain ratios, formulated for the use in the treatment of PTE.

The present invention relates to a chewing gum for mucosal delivery of cannabinoids, the chewing gum including water-soluble chewing gum ingredients and water-insoluble gum base, wherein the gum base has one or more natural resins in an amount of 10-40% by weight of the gum base, one or more elastomers in an amount of 3-30% by weight of the gum base, and one or more elastomer plasticizers in an amount of 8-50% by weight of the gum base, and wherein the water-soluble chewing gum ingredients include one or more sugar alcohols in an amount of 35-80% by weight of the chewing gum, and wherein the chewing gum has one or more cannabinoids.

Described are liquid compositions that contain a desired (e.g., extracted) plant material such as cannabinoid, terpene, terpenoid, or the like, contained, e.g., dissolved, suspended, or emulsified, in the liquid, which contains surfactant; methods of preparing these types of liquid compositions; and methods of processing this type of liquid composition to collect, isolate, concentrate, or purify a desired target material contained in the liquid composition.

The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.

Methods are provided for the synthesis of cannabinoids, including cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabidiolic acid (CBDA), cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidivarin (CBDV), cannabidibutol (CBD-C4), dihydrocannabidiol (DCBD), tetrahydrocannabivarin (THCV), analogs thereof, and precursors to the foregoing. One method employs phloroglucinol or a phloroglucinol analog as a starting material. The syntheses are stereospecific, efficient, selective, and cost-effective, with little or no potential for generation of THC ((−)-trans-Δ9-tetrahydro-cannabinol) or any other psychoactive side product. Telescoped syntheses are also provided, as are new cannabinoids, pharmaceutical formulations, and methods of use.

This invention provides methods for the synthesis of cannabidiol and its analogues, as well as related compounds, formulations, and methods of use. [Solution] Methods are provided for the synthesis of oliveitol, oliveitol analogs, cannabidiol (CBD), CBD analogs, and other cannabinoids. One method uses phloroglucinol or phloroglucinol analogs as starting materials. The synthesis is stereospecific, efficient, selective, cost-effective, and THC((-)-trans-Δ 9 There is little to no possibility of generating (tetrahydro-cannabinol) or any other psychoactive by-products. Shortened synthesis is also provided, as well as new cannabinoids, pharmaceutical formulations, and methods of use.

The present invention relates to a process for purifying cannabinoids, specifically cannabidiol, in a substantially pure form from herbal material. This process involves a sequence of purification steps including winterization, co-crystallization, dissociation, decarboxylation, and crystallization. Cannabidiol is purified from an extract of herbal material containing approximately 50-70% cannabidiolic acid (CBDA) and 10-20% cannabidiol (CBD), along with other cannabinoids. The substantially pure form of cannabidiol can be used in medicaments for treating various diseases or conditions. The invention also relates to co-crystals of L-proline and cannabidiolic acid and their use in obtaining substantially pure cannabidiol free from tetrahydrocannabinol (THC).

The invention provides a pharmaceutical formulation containing a particulate porous adsorbent selected from the group of aluminosilicates and their salts, with a neutral or basic pH and a particle size between 50 and 800 μm, onto which a mixture of polyoxyethylene sorbitan monooleate (polysorbate 80) is applied with at least one cannabinoid selected from cannabidiol, cannabigerol, cannabinol, D9-THC, and D8-THC. This formulation improves the bioavailability and release profile of the cannabinoids.

The compositions and methods of the disclosure can be used to produce a cannabinoid in a host cell, such as a yeast cell. For example, the disclosure features host cells (e.g., yeast cells) modified to express one or more enzymes of a cannabinoid biosynthetic pathway, such as an acyl activating enzyme (AAE), a tetraketide synthase (TKS), a cannabigerolic acid synthase (CBGaS), and / or an olivetolic acid cyclase (OAC).

The present disclosure relates to new cannabinoid derivatives and precursors and processes for their preparation. The disclosure also relates to pharmaceutical and analytical uses of the new cannabinoid derivatives.

Preparation of cannabinoid formulations containing: Δ9-tetrahydrocannabinol (Δ9-THC), Δ8-tetrahydrocannabinol (Δ8-THC), Δ9-tetrahydrocannabinolic acid (THCa), cannabidiol (CBD), cannabidiolic acid (CBDa), cannabigerol (CBG), cannabichromene (CBC) and cannabinol (CBN), either alone or in combinations henceforth known as cannabis, have been created using an emulsification process to encapsulate cannabinoids. The aqueous-based method involves micellular encapsulation of cannabinoids, a method that has been used to increase the bioavailability of poorly permeable, lipophilic drugs. The present invention demonstrates the viability of transdermal delivery with gels and patches for consistent and sustained cannabinoid dosing.

Compositions for the extended release of one or more cannabinoids, in which the compositions comprise a population of particles. Each particle may comprise the one or more cannabinoids, one or more drug-releasing agents, one or more surfactants, and a core. The core may comprise a porous bead. The one or more cannabinoids may comprise Δ9-tetrahydrocannabinol, cannabidiol, or a combination thereof.

The solubility of cannabinoid in water is improved.A solid composition according to an embodiment contains an amorphous cannabinoid, a sucrose fatty acid ester having a monoester ratio of 85 mass % or more, and a water-soluble polymer. The solid composition can be prepared by, for example, dissolving a cannabinoid, a sucrose fatty acid ester having a monoester ratio of 85 mass % or more, and a water-soluble polymer in a solvent, and removing the solvent from the resultant solution.

The present invention relates to a solid oral pharmaceutical for Tetrahydrocannabinol (API) or any other Cannabinoid (API) with a novel, well defined method to enhance solubility of active pharmaceutical ingredients (API) with low solubility in aqueous media and use those enhanced API in a new approach of preparing modified and / or sustained release pharmaceutical formulation for API which are regularly not suitable for sustained release formulations because of their low solubility. This invention is applicable for small molecule API (molecular weight < 1000) for which the solubility can be enhanced by formation of a e.g., Cyclodextrin Complex regardless which Cyclodextrin or derivate thereof is employed according to the method described in this invention. Tetrahydrocannabinol and other Cannabinoids can be found in a wide range of indications like pain relief, insomnia, anti- depression and others.

Cannabinoid compositions formulated for use in the treatment of post-traumatic epilepsy (PTE) are disclosed. These compositions include cannabidiol (CBD), cannabigerol (CBG), and tetrahydrocannabinol (THC) as their main components, which may be isolated, purified, or extracted from cultivars and mixed together. The compositions include CBD, CBG, and THC in specific proportions, formulated for use in the treatment of PTE.

A tableted chewing gum composition for oral administration of cannabinoids includes a plurality of particles, including a first population of particles having water-insoluble gum base and a second population of particles having water-soluble chewing gum ingredients. The composition constitutes at least two layers, where a first layer of the composition has water-insoluble gum base and a second layer of the composition, which is cohered to and adjacent to the first layer, has water-soluble chewing gum ingredients. The second layer is free of water-insoluble gum base, and the composition includes one or more cannabinoids.

This application relates to a method for preparing cannabidiol epoxide and its application. The method includes obtaining cannabidiol, adding it to a buffer solution containing a surfactant, treating it under preset conditions to obtain a crude product, and purifying the crude product by silica gel column gradient chromatography to obtain the finished cannabidiol epoxide. Compared with the traditional method of oxidation using peroxide agents, the process of preparing cannabidiol epoxide in this invention can utilize natural oxidation in air in one step, which is greener, more environmentally friendly, and safer. It also ensures ease of operation while reducing production costs. Furthermore, using cannabidiol (CBD) as a raw material, which has a relatively mature extraction process, makes it easier to obtain compared to other naturally occurring cannabinoids with extremely low content.

Cannabinoid analogs disclosed herein may exhibit antibacterial and anti-inflammatory properties. Pharmaceutical compositions comprising the cannabinoid analogs may be used to treat bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA) infections, as well as various disorders associated with chronic inflammation, such as arthritis. In some aspects, a pharmaceutical composition may be administered to an individual who has been exposed or is at risk of exposure to Bacillus anthracis or Bacillus anthracis spores.

A pharmaceutically or nutraceutically acceptable formulation contains a cannabinoid which may be a full spectrum or partial spectrum cannabis extract, tetrahydrocannabinol (THC), an analog of THC, cannabidiol (CBD), an analog of CBD, ora combination thereof and at least one nootropic agent mixed in a carrier medium. A method of making the formulation mixingsaid formula and heatingthe formulation above room temperature until the mixture is homogenous. Additional supplements may be added to each formulation. The formulation may have a carrier medium suitable to be used in capsule, dissolvable tablet, vaporizer, spray, inhaler, tincture, beverage or any other suitable application.

This invention is directed to crystalline forms of cannabinoid acids, producing crystalline forms, and methods of use thereof.

The effect of a cationic hydrophobic polymer on improving sensitivity and selectivity toward the electrochemical detection of cannabinoid analytes, e.g. Δ9-tetrahydrocannabinol (Δ⁹-THC), has been investigated. Herein we report a rapid, inexpensive and stable method for the detection of 10 – 1000 ng / mL of cannabinoid analytes, e.g. Δ9-tetrahydrocannabinol (Δ⁹-THC), 5 in buffer solutions and in human saliva.

The present invention relates to the medical device and pharmaceutical industry, as well as related fields such as dermatology and cosmetics, since the formulation includes natural anti-inflammatory components and high viscous solvents such as polysorbate and glycerol, which work synergistically to enhance drug retention on the eye surface, minimize visual blur on instillation and reduce dosage frequency. The present invention describes a topical delivery of a cannabinoid-based ophthalmic composition that includes Tetrahydrocannabinol (THC)-based molecule isolated or associated with Cannabidiol (CBD). In another embodiment of the preferred invention, the formulation further comprises one or more synergistic agents, including but not limited to steroidal and non-steroidal anti-inflammatory and antihistamines pharmaceutical formulations.

This disclosure generally relates to gas-phase methods to simultaneously purify and decarboxylate cannabinoids in about two seconds, which are about 100-10,000 times more efficient than conventional purification and decarboxylation strategies. The methods also recover thermolabile cannabinoids such as cannabigerol at significantly higher yields than conventional methods.

To provide a stable, non-degradable composition comprising a pharmaceutical grade, inhalable, soluble, and highly bioavailable API.SOLUTION: A composition comprising a pharmaceutical grade cyclodextrin encapsulated active pharmaceutical ingredient (API) having a purity of 99.9% and an increased bioavailability of 200% compared to a formulation of a non-cyclodextrin encapsulated active pharmaceutical ingredient, and a pharmaceutically acceptable carrier, excipient, emulsifier, and / or binder, A water-soluble, stable, non-degradable, edible, inhalable, soluble or drinkable composition in which the active pharmaceutical ingredient is a cannabinoid and the cannabinoid is one or more of cannabidiol (CBD) or (-) - trans - δ 9-tetrahydrocannabinol (δ 9-THC).SELECTED DRAWING: None

Various aspects of this patent document relate to cannabinoid ions that are dissolved in glycerol, in which the cannabinoid ions are not carboxylates. Such compositions are suitable for the oral and topical administration of the cannabinoid ions. Glycerol is more hydrophobic than water, which enables higher concentrations of the cannabinoid ions in glycerol relative to water. Glycerol is also more appealing for oral administration than other hydrophobic solvents such as ethanol.

The invention relates to a method of extracting cannabinoids from plant waxes. The method includes contacting plant waxes with an immiscible solvent combination comprising a non-polar solvent and a polar solvent. The immiscible solvents are separated to yield a wax-rich non-polar fraction and a cannabinoid- rich polar fraction. The cannabinoid-rich polar fraction is subsequently contacted with a sufficient volume of an antisolvent, thereby causing precipitation of cannabinoids. The precipitated cannabinoids may be collected and subjected to optional further processing. The method provides an efficient and selective approach to isolating cannabinoids from wax-containing plant material.